Current Report Filing (8-k)
April 11 2017 - 8:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): April 11, 2017
VBI
VACCINES INC.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
(State
or other jurisdiction
of
incorporation)
|
|
000-37769
(Commission
File
Number)
|
|
N/A
(IRS
Employer
Identification
No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
(Address
of principal executive offices)
|
|
02142
(Zip
Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
|
(Former
Name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure.
On
April 11, 2017, David E. Anderson, Ph.D., the Chief Scientific Officer of VBI Vaccines Inc. (the “Company”), and Francisco
Diaz-Mitoma, M.D., Ph.D, the Chief Medical Officer of the Company, will present updates on the Company’s eVLP Platform and
Sci-B-Vac™ vaccine, respectively, at the World Vaccine Congress in Washington, D.C.
The
presentations are furnished herewith as Exhibits 99.1 and 99.2 and are incorporated by reference in this Item 7.01. The presentations
will be available on the Company’s website at www.vbivaccines.com.
The
information disclosed under this Item 7.01, including Exhibits 99.1, and 99.2 hereto, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with
the U.S. Securities and Exchange Commission (the “SEC”) nor incorporated by reference into any filing made under the
Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1*
|
|
World
Vaccine Congress Presentation of VBI Vaccines Inc. by David E. Anderson, Ph.D., dated April 2017.
|
|
|
|
99.2*
|
|
World
Vaccine Congress Presentation of VBI Vaccines Inc. by Francisco Diaz-Mitoma, M.D., Ph.D., dated April 2017.
|
*
Furnished herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI Vaccines Inc.
|
|
|
|
Date:
April 11, 2017
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff
Baxter
|
|
|
President
and Chief Executive Officer
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1*
|
|
World
Vaccine Congress Presentation of VBI Vaccines Inc. by David E. Anderson, Ph.D., dated April 2017.
|
|
|
|
99.2*
|
|
World
Vaccine Congress Presentation of VBI Vaccines Inc. by Francisco Diaz-Mitoma, M.D., Ph.D., dated April 2017.
|
*
Furnished herewith
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Sep 2023 to Sep 2024